Dr. Layman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1515 Holcombe Blvd
Unit 1354
Houston, TX 77030Phone+1 713-745-8401Fax+1 713-794-5039
Summary
- Dr. Rachel Layman, based in Houston, TX, specializes in Oncology with a particular focus on breast cancer and cancer genetics/cancer risk assessment. She completed her fellowship in Hematology and Medical Oncology at the University of Michigan Health System and her residency in Internal Medicine at Case Western Reserve University/University Hospitals Cleveland Medical Center. Dr. Layman's expertise includes medical oncology, breast cancer, familial breast cancer, hormone receptor positive breast cancer, and inflammatory breast cancer. She has contributed extensively to research within her field, authoring numerous publications in leading oncology journals and conducting several clinical trials. Notably, Dr. Layman was recognized with the CMS Meaningful Use Stage 1 Certification from EpicCare Ambulatory EMR, Epic Systems Corporation in 2012-2013.
Education & Training
University of MichiganFellowship, Hematology and Medical Oncology, 2004 - 2008
Case Western Reserve University/University Hospitals Cleveland Medical CenterResidency, Internal Medicine, 2001 - 2004
Case Western Reserve University School of MedicineClass of 2001
Certifications & Licensure
FL State Medical License 2021 - Present
GA State Medical License 2023 - 2026
TX State Medical License 2016 - 2026
WA State Medical License 2023 - 2026
AZ State Medical License 2023 - 2025
LA State Medical License 2023 - 2025
MS State Medical License 2023 - 2025- American Board of Internal Medicine Medical Oncology
- Join now to see all
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Bendamustine and Erlotinib in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Breast Cancer Start of enrollment: 2009 Apr 01
- A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer Start of enrollment: 2010 Aug 13
- Paclitaxel and BKM120 Before Surgery in Treating Patients With Stage II or III Estrogen Receptor-Positive and HER2-Negative Breast Cancer Start of enrollment: 2014 Aug 01
- Join now to see all
Publications & Presentations
PubMed
- 51 citationsReal-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2- metastatic breast cancer.Hope S Rugo, Adam Brufsky, Xianchen Liu, Benjamin Li, Lynn McRoy
NPJ Breast Cancer. 2022-10-11 - 41 citationsSETER/PR: a robust 18-gene predictor for sensitivity to endocrine therapy for metastatic breast cancer.Bruno Valentin Sinn, Chunxiao Fu, Rosanna Lau, Jennifer K. Litton, Tsung-Heng Tsai
NPJ Breast Cancer. 2019-05-30 - 45 citationsClinical and Translational Results of a Phase II, Randomized Trial of an Anti–IGF-1R (Cixutumumab) in Women with Breast Cancer That Progressed on Endocrine TherapyWilliam J. Gradishar, Denise A. Yardley, Rachel M. Layman, Joseph A. Sparano, Ellen Chuang
Clinical Cancer Research. 2016-01-15
Press Mentions
Pfizer Presents New Evidence of IBRANCE® (Palbociclib) Effectiveness in HR+, HER2- Metastatic Breast Cancer Patients in Four Real-World Studies at ESMO Congress 2019September 24th, 2019
Mom, 30, Details Symptoms of Rare Type of Breast Cancer That Doctors MisdiagnosedOctober 12th, 2023
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
